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The epidermal growth factor receptor
(EGFR), along with ErbB2 (HER2/Neu),
ErbB3 (HER3), and ErbB4 (HER4), is a
member of a subclass of cell surface
receptors with intrinsic tyrosine kinase
activity, known as receptor tyrosine kinas-
es (RTKs) (reviewed in Schlessinger,
2000). Receptors of the EGFR subclass
play critical roles in normal embryonic
development, and as mediators of cell
proliferation, they can also drive the
growth of tumors through ligand or recep-
tor overexpression or a receptor gain-of-
function mutation (reviewed in Yarden
and Sliwkowski, 2001). Excessive prolif-
erative signaling from EGFR and ErbB2
has been implicated in a broad spectrum
of epithelial carcinomas, including breast,
ovarian, head and neck, lung, pancreatic,
and colorectal.
Two therapeutic strategies have met
with success for suppressing aberrant
EGFR and ErbB2 signaling: antibody tar-
geting of the extracellular region of the
receptors and small-molecule inhibition of
the cytoplasmic tyrosine kinase domains
(reviewed in Mendelsohn and Baselga,
2003). The antibody approach provides
high target specificity, but because the
therapeutic agent is a protein, there are
greater challenges in drug development.
Small-molecule inhibitors are relatively
less difficult to convert into a drug, but
because of their small size, a suitably
deep pocket/cleft in the target protein is
usually necessary to achieve high affinity
binding and specificity. For EGFR and
ErbB2 (and other protein kinases), the
ATP binding cleft of the tyrosine kinase
domain satisfies this requirement.
Trastuzumab (Herceptin), a mono-
clonal antibody that targets ErbB2, was
approved by the Food and Drug
Administration (FDA) in 1998 for the
treatment of metastatic breast cancers
overexpressing ErbB2. The monoclonal
antibody cetuximab (Erbitux), which tar-
gets EGFR, was approved last year by
the FDA for advanced-stage, EGFR-dri-
ven colorectal cancers. Two small-mole-
cule inhibitors of EGFR/ErbB2 have
been approved by the FDA, gefitinib
(Iressa) and erlotinib (Tarceva). Gefitinib
and erlotinib, both of which target the
ATP binding cleft of EGFR, have been
approved for advanced non-small cell
lung cancer. Importantly, recent studies
of non-small cell lung cancer patients
have shown that gefitinib is only effective
(and then, highly effective) for a subpop-
ulation of these patients, those who har-
bor particular mutations in the tyrosine
kinase domain of EGFR (reviewed in
Minna et al., 2004). Several other drugs
targeting EGFR and ErbB2 are at vari-
ous stages of clinical trials.
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The epidermal growth factor receptor (EGFR) drives tumor growth in a subset of human epithelial carcinomas. A crystallo-
graphic study by Li et al. in this issue of Cancer Cell provides the molecular basis for inhibition of EGFR by cetuximab
(Erbitux), a monoclonal antibody that has been approved by the Food and Drug Administration as a therapeutic for
advanced-stage colorectal cancers. Cetuximab targets one of the ligand binding domains of EGFR, thus preventing ligand
activation of the receptor.
Figure 1. Ligand activation of EGFR and anti-
body targeting of EGFR and ErbB2
The ectodomains of EGFR and ErbB2 are
shown in surface representation, with
domain I (L1) colored light green, domain II
(CR1) colored light purple, domain III (L2)
colored dark green, and domain IV (CR2)
colored dark purple. The dimerization arm in
domain II is indicated by a dashed circle in
AC. For each antibody Fab (DF), the Cα
trace of the light chain is colored yellow and
the Cα trace of the heavy chain is colored
cyan. The receptor ectodomains have been
oriented such that the position of domain IV
is common. The membrane bilayer is repre-
sented (not to scale) by the yellow spheres. 
A: Structure of the unbound EGFR
ectodomain (autoinhibited, tethered state). 
B: Structure of the 1:1 EGF:EGFR ectodomain
complex (dimerization-competent state).
The Cα trace of EGF is colored orange. 
C: Structure of the 2:2 EGF:EGFR ectodomain
complex (dimerized, activated state). The 2-
fold axis of the dimer is vertical, in the plane
of the page. 
D: Structure of cetuximab bound to domain
III of the EGFR ectodomain. 
E: Structure of trastuzumab bound to domain
IV of the ErbB2 ectodomain. 
F: Structure of pertuzumab bound to domain
II of the ErbB2 ectodomain.
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The extracellular region (ectodomain)
of EGFR and its family members is com-
posed of two types of domains, a so-
called L domain and a cysteine-rich (CR)
domain. These domains are arranged (N-
to C-terminal) as two repeats of an L-CR
pair: L1-CR1-L2-CR2. The ligand binding
site comprises domains I (L1) and III (L2),
the discontinuous (in a linear domain
sense) nature of which hints at a compli-
cated ligand-mediated activation process.
The natural ligands for EGFR include
EGF, transforming growth factor-α
(TFGα), amphiregulin, and betacellulin
(among several others), while neuregulins
are the ligands for ErbB3 and ErbB4.
Several differences among the four
EGFR family members are notable. One
receptor, ErbB3, is devoid of catalytic
activity, even though it possesses a tyro-
sine kinase domain (critical catalytic
residues have been substituted), and one
receptor, ErbB2, is ligandless. These
peculiarities figure prominently in an
important mechanistic feature of this 
subclass of RTKs: heterodimerization
(reviewed in Schlessinger, 2000; Yarden
and Sliwkowski, 2001). Through het-
erodimerization, ErbB3, without an active
kinase domain, can still be activated
(phosphorylated) by ligandless ErbB2,
which will recruit an ErbB3-specific set of
downstream signaling proteins to the
receptor heterodimer.
Over the past several years, a bur-
geoning of structural data has illuminat-
ed the molecular mechanisms governing
ligand-mediated activation of EGFR and
related family members (reviewed in
Burgess et al., 2003). Crystal structures
of the ectodomains of EGFR, ErbB2,
and ErbB3, in various ligand-bound
states, have revealed that binding of
monomeric EGF or TGFα to the EGFR
ectodomain stabilizes a conformation of
the ectodomain that is competent for
homodimerization or for heterodimeriza-
tion with other EGFR family members.
More precisely, a dimerization arm in
domain II (CR1) of the receptor, which is
sequestered by domain IV (CR2) of the
unliganded receptor (tethered state;
Figure 1A), becomes exposed upon
EGF binding to domains I (L1) and III
(L2) (Figure 1B). Rather than a 2:2 lig-
and:receptor complex in which the lig-
ands bridge the two receptors, a
common mode of RTK activation, the
receptors themselves are the bridging
elements in the 2:2 EGF:EGFR complex
(Figure 1C). The stabilized receptor
dimer then undergoes trans-phosphory-
lation on specific tyrosine residues in the
cytoplasmic domain.
In the paper by Li et al. (2005), the
crystal structure of the EGFR
ectodomain in complex with the antigen
binding fragment (Fab) of cetuximab is
presented, which reveals that the anti-
body binds exclusively to domain III (L2)
of the receptor (Figure 1D). A compari-
son with a previous EGFR structure with
bound EGF indicates that the cetuximab
binding footprint on domain III overlaps
that of EGF on domain III. Through in
vitro binding studies, Li et al. (2005)
show that the cetuximab Fab binds ?50
times tighter to the (soluble) EGFR
ectodomain than does EGF. Thus, the
principal mechanism by which cetux-
imab inhibits EGFR signaling and elicits
an antitumor effect is likely through direct
ligand competition.
A second inhibitory mechanism may
also be operative as a consequence of
cetuximab binding to domain III of
EGFR. To adopt a dimerization-compe-
tent conformation, in which the dimeriza-
tion arm of domain II is exposed,
domains I and III must be juxtaposed.
For EGFR, ErbB3, and ErbB4, this is
accomplished through ligand binding
(Figure 1B), whereas ErbB2 adopts this
conformation constitutively, without lig-
and (Figures 1E and 1F). Cetuximab
binding to domain III of EGFR will,
through steric hindrance, prevent the
spontaneous (ligand-independent) juxta-
position of domains I and III (compare
Figures 1B and 1D), thereby thwarting
any basal EGFR dimerization and sig-
naling. The relative contribution of this
mechanism to the overall antitumor
effect of cetuximab is difficult to assess.
The crystal structure of cetuximab
bound to the EGFR ectodomain is the
third structure of a therapeutic antibody
bound to the ectodomain of an EGFR
family member. The other two antibodies
are trastuzumab and pertuzumab
(Omnitarg), both of which (Fab frag-
ments) were cocrystallized with the
ErbB2 ectodomain (Cho et al., 2003;
Franklin et al., 2004). The mode of anti-
body binding is distinct in each case
(Figures 1D–1F). As discussed above,
cetuximab binds to domain III (L2) of
EGFR, whereas trastuzumab and per-
tuzumab bind to domains IV (CR2) and II
(CR1), respectively, of ErbB2. Moreover,
cetuximab binds to the tethered state of
EGFR, whereas trastuzumab and per-
tuzumab bind to the untethered, dimer-
ization-competent state of ErbB2. The
antitumor activity of trastuzumab
appears to derive from several mecha-
nisms, including stimulation of ErbB2
endocytosis and antibody-mediated
cytotoxicity, whereas pertuzumab direct-
ly interferes with the ability of ErbB2 to
heterodimerize.
This is an exciting and cautiously
optimistic time in the quest to develop
anticancer therapeutics designed to tar-
get specific protein tyrosine kinases,
best exemplified by the success of ima-
tinib (Gleevec) in inhibiting Bcr-Abl in
chronic myeloid leukemia (Druker et al.,
2001).Through a better understanding of
the cellular signaling processes underly-
ing tumorigenesis and metastasis, and
of the precise molecular interactions
between a drug—antibody or small mol-
ecule—and its kinase target, our arsenal
of rationally designed therapeutics
should continue to expand.
Stevan R. Hubbard
Structural Biology Program
Skirball Institute of Biomolecular Medicine
New York University School of Medicine
New York, New York 10016
E-mail: hubbard@saturn.med.nyu.edu
Selected reading
Burgess, A.W., Cho, H.S., Eigenbrot, C.,
Ferguson, K.M., Garrett, T.P., Leahy, D.J.,
Lemmon, M.A., Sliwkowski, M.X., Ward, C.W.,
and Yokoyama, S. (2003). Mol. Cell 12, 541–552.
Cho, H.S., Mason, K., Ramyar, K.X., Stanley,
A.M., Gabelli, S.B., Denney, D.W., Jr., and Leahy,
D.J. (2003). Nature 421, 756–760.
Druker, B.J., Talpaz, M., Resta, D.J., Peng, B.,
Buchdunger, E., Ford, J.M., Lydon, N.B.,
Kantarjian, H., Capdeville, R., Ohno-Jones, S., et
al. (2001). N. Engl. J. Med. 344, 1031–1037.
Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy,
D.J., de Vos, A.M., and Sliwkowski, M.X. (2004).
Cancer Cell 5, 317–328.
Li, S., Schmitz, K.R., Jeffrey, P.D., Wiltiuz, J.J.W.,
Kussie, P., and Ferguson, K.M. (2005). Cancer
Cell, this issue.
Mendelsohn, J., and Baselga, J. (2003). J. Clin.
Oncol. 21, 2787–2799.
Minna, J.D., Gazdar, A.F., Sprang, S.R., and
Herz, J. (2004). Science 304, 1458–1461.
Schlessinger, J. (2000). Cell 103, 211–225.
Yarden, Y., and Sliwkowski, M.X. (2001). Nat.
Rev. Mol. Cell Biol. 2, 127–137.
DOI: 10.1016/j.ccr.2005.04.004
P R E V I E W S
